DK3355919T3 - Kombinationsterapi som anvender inhibitorer af human vækst- og differentieringsfaktor 15 (gdf-15) og immun-checkpoint-blockers - Google Patents

Kombinationsterapi som anvender inhibitorer af human vækst- og differentieringsfaktor 15 (gdf-15) og immun-checkpoint-blockers Download PDF

Info

Publication number
DK3355919T3
DK3355919T3 DK16778750.6T DK16778750T DK3355919T3 DK 3355919 T3 DK3355919 T3 DK 3355919T3 DK 16778750 T DK16778750 T DK 16778750T DK 3355919 T3 DK3355919 T3 DK 3355919T3
Authority
DK
Denmark
Prior art keywords
gdf
inhibitors
combination therapy
immune checkpoint
human growth
Prior art date
Application number
DK16778750.6T
Other languages
English (en)
Inventor
Jörg Wischhusen
Markus Haake
Tina Schäfer
Martina Selle
Reinhard Dummer
Matthias Mehling
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57121227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3355919(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1517531.8A external-priority patent/GB201517531D0/en
Priority claimed from GBGB1607801.6A external-priority patent/GB201607801D0/en
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Application granted granted Critical
Publication of DK3355919T3 publication Critical patent/DK3355919T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16778750.6T 2015-10-02 2016-09-30 Kombinationsterapi som anvender inhibitorer af human vækst- og differentieringsfaktor 15 (gdf-15) og immun-checkpoint-blockers DK3355919T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1517531.8A GB201517531D0 (en) 2015-10-02 2015-10-02 Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
GBGB1607801.6A GB201607801D0 (en) 2016-04-29 2016-04-29 Combination therapy using inhibitors of human Growth and Differentiation Factor 15 (GDF-15) and immune checkpoint blockers
PCT/EP2016/073520 WO2017055613A2 (en) 2015-10-02 2016-09-30 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers

Publications (1)

Publication Number Publication Date
DK3355919T3 true DK3355919T3 (da) 2022-12-19

Family

ID=57121227

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16778750.6T DK3355919T3 (da) 2015-10-02 2016-09-30 Kombinationsterapi som anvender inhibitorer af human vækst- og differentieringsfaktor 15 (gdf-15) og immun-checkpoint-blockers

Country Status (22)

Country Link
US (2) US11464856B2 (da)
EP (2) EP3355919B1 (da)
JP (3) JP6925326B2 (da)
KR (1) KR20180054868A (da)
CN (2) CN108463246A (da)
AU (2) AU2016333539B2 (da)
BR (1) BR112018006218A2 (da)
CA (1) CA3000293A1 (da)
DK (1) DK3355919T3 (da)
EA (1) EA201890850A1 (da)
ES (1) ES2937167T3 (da)
FI (1) FI3355919T3 (da)
HK (1) HK1256067A1 (da)
HR (1) HRP20221530T1 (da)
HU (1) HUE060762T2 (da)
IL (2) IL299478A (da)
LT (1) LT3355919T (da)
MD (1) MD3355919T2 (da)
PL (1) PL3355919T3 (da)
PT (1) PT3355919T (da)
SI (1) SI3355919T1 (da)
WO (1) WO2017055613A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886207C (en) * 2012-09-26 2021-01-05 Jorg Wischhusen Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
CN112162097B (zh) * 2020-07-24 2022-04-01 广州医科大学 Gdf1作为评估pd-1单抗治疗效果的生物标志物
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
CN112778419A (zh) * 2021-02-01 2021-05-11 重庆中元汇吉生物技术有限公司 抗ck-mb的抗体或其抗原结合部分及其应用
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2024052532A1 (en) 2022-09-08 2024-03-14 Catalym Gmbh Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070051A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
US8192735B2 (en) 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20070128636A1 (en) 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
JP2010536717A (ja) 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
MX2011003184A (es) 2008-09-29 2011-04-21 Roche Glycart Ag Anticuerpos contra il17 humana y usos de los mismos.
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
CA2886207C (en) 2012-09-26 2021-01-05 Jorg Wischhusen Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
EA038645B1 (ru) 2012-12-21 2021-09-28 Авео Фармасьютикалз, Инк. Антитела к gdf15
EP3798316A3 (en) 2013-03-15 2021-06-09 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
US20150104470A1 (en) * 2013-10-11 2015-04-16 Neil H. Riordan Immune modulation by peri-lymphatic or intra-lymphatic cell therapy
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
PT3197493T (pt) 2014-09-25 2021-06-04 Aveo Pharmaceuticals Inc Métodos para reverter a caquexia e prolongar a sobrevivência que compreendem a administração de um modulador de gdf15 e um agente anti-carcinogénico
CN112912395A (zh) 2018-08-20 2021-06-04 辉瑞公司 抗gdf15抗体、组合物和使用方法

Also Published As

Publication number Publication date
AU2016333539A1 (en) 2018-05-10
FI3355919T3 (fi) 2023-01-13
WO2017055613A2 (en) 2017-04-06
EP3355919B1 (en) 2022-12-07
CN108463246A (zh) 2018-08-28
MD3355919T2 (ro) 2023-02-28
JP7443298B2 (ja) 2024-03-05
IL299478A (en) 2023-02-01
CN117883572A (zh) 2024-04-16
JP2024054251A (ja) 2024-04-16
JP2018534266A (ja) 2018-11-22
SI3355919T1 (sl) 2023-04-28
PL3355919T3 (pl) 2023-03-20
PT3355919T (pt) 2023-01-06
EP4218809A2 (en) 2023-08-02
ES2937167T3 (es) 2023-03-24
IL258393B1 (en) 2023-04-01
EA201890850A1 (ru) 2018-09-28
LT3355919T (lt) 2023-02-10
EP4218809A3 (en) 2023-08-09
US11464856B2 (en) 2022-10-11
CA3000293A1 (en) 2017-04-06
HRP20221530T1 (hr) 2023-03-17
JP6925326B2 (ja) 2021-08-25
WO2017055613A3 (en) 2017-07-06
EP3355919A2 (en) 2018-08-08
IL258393A (en) 2018-05-31
HK1256067A1 (zh) 2019-09-13
AU2023202602A1 (en) 2023-05-18
JP2021176891A (ja) 2021-11-11
HUE060762T2 (hu) 2023-04-28
BR112018006218A2 (pt) 2018-10-09
US20230093412A1 (en) 2023-03-23
US20190160169A1 (en) 2019-05-30
IL258393B2 (en) 2023-08-01
AU2016333539B2 (en) 2023-02-23
KR20180054868A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
DK3355919T3 (da) Kombinationsterapi som anvender inhibitorer af human vækst- og differentieringsfaktor 15 (gdf-15) og immun-checkpoint-blockers
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3707159T3 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
DK3389564T3 (da) Hjerteklapprotese
DK3285055T3 (da) Magnetostriktive sensorer uden kontakt og fremgangsmåder til anvendelse af sensorerne
DK3560098T3 (da) Fotovoltaik-anlæg og tilhørende anvendelse
DK3570786T3 (da) Skulderimplantatkomponenter
DK3351239T3 (da) Prostamid-indeholdende intraokulære implantater og fremgangsmåder til anvendelse deraf
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3481581T3 (da) Metalwiretilførselssystem og fremgangsmåde
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3346056T3 (da) Rengøringssystem og fremgangsmåde
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf
DK3474799T3 (da) Medicinsk forbinding, medicinsk forbindingssystem og fremgangsmåde til reduktion af arbejdsbelastningen for plejepersonale
DK3325027T3 (da) Medicinsk implantat
MA50358A (fr) Sémaglutide en thérapie médicale
DK3332734T3 (da) Tandimplantat med gevind
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
MA43223A (fr) Prothèse endoluminale implantable
KR20180084928A (ko) 특히 전류의 도움으로 인간 케라틴 물질을 처리하기 위한 디바이스
DK3353581T3 (da) Optisk lag og lampe med et sådant lag
MA53889A (fr) Prothèse ligamentaire